Report Content
Chapter 1 Methodology & Scope
1.1 Market scope & definitions
1.2 Research design
1.2.1 Research approach
1.2.2 Data collection methods
1.3 Base estimates & calculations
1.3.1 Base year calculation
1.3.2 Key trends for market estimation
1.4 Forecast model
1.5 Primary research and validation
1.5.1 Primary sources
1.5.2 Data mining sources
Chapter 2 Executive Summary
2.1 Industry 3600 synopsis
Chapter 3 Industry Insights
3.1 Industry ecosystem analysis
3.2 Industry impact forces
3.2.1 Growth drivers
3.2.1.1 Increasing incidence of poisoning and overdoses
3.2.1.2 Growing awareness and training programs
3.2.1.3 Technological advancements
3.2.1.4 Increasing research and development activities
3.2.2 Industry pitfalls & challenges
3.2.2.1 Adverse effects and safety concerns
3.2.2.2 High cost of antidote development and production
3.3 Growth potential analysis
3.4 Technological landscape
3.5 Regulatory landscape
3.6 Porter's analysis
3.7 PESTEL analysis
Chapter 4 Competitive Landscape, 2023
4.1 Introduction
4.2 Company market share analysis
4.3 Competitive positioning matrix
4.4 Strategy outlook matrix
Chapter 5 Market Estimates and Forecast, By Type, 2021 – 2032 ($ Mn)
5.1 Key trends
5.2 Chemical antidote
5.3 Physical antidote
5.4 Pharmacological antidote
Chapter 6 Market Estimates and Forecast, By Route of Administration, 2021 – 2032 ($ Mn)
6.1 Key trends
6.2 Injectable
6.3 Oral
6.4 Topical
Chapter 7 Market Estimates and Forecast, By Application, 2021 – 2032 ($ Mn)
7.1 Key trends
7.2 Drug overdose
7.3 Chemical poisoning
7.4 Food poisoning
7.5 Other applications
Chapter 8 Market Estimates and Forecast, By End-Use, 2021 – 2032 ($ Mn)
8.1 Key trends
8.2 Hospitals
8.3 Clinics
8.4 Home care settings
8.5 Other end-users
Chapter 9 Market Estimates and Forecast, By Region, 2021 – 2032 ($ Mn)
9.1 Key trends
9.2 North America
9.2.1 U.S.
9.2.2 Canada
9.3 Europe
9.3.1 Germany
9.3.2 UK
9.3.3 France
9.3.4 Spain
9.3.5 Italy
9.3.6 Netherlands
9.3.7 Rest of Europe
9.4 Asia Pacific
9.4.1 Japan
9.4.2 China
9.4.3 India
9.4.4 Australia
9.4.5 South Korea
9.4.6 Rest of Asia Pacific
9.5 Latin America
9.5.1 Brazil
9.5.2 Mexico
9.5.3 Argentina
9.5.4 Rest of Latin America
9.6 Middle East and Africa
9.6.1 Saudi Arabia
9.6.2 South Africa
9.6.3 UAE
9.6.4 Rest of Middle East and Africa
Chapter 10 Company Profiles
10.1 Alvogen
10.2 Aurobindo Pharma Limited
10.3 Akorn Operating Company LLC
10.4 Baxter International, Inc.
10.5 Daiichi Sanko Group
10.6 Dr. Reddy’s Laboratories Ltd.
10.7 Endo International plc
10.8 Emergent Biosolutions Inc.
10.9 Fresenius SE & Co. KGaA
10.10 Hikma Pharmaceuticals PLC
10.11 Nichi-Iko Pharmaceutical Co., Ltd.
10.12 Novartis AG
10.13 Pfizer Inc.
10.14 Viatris Inc.
10.15 Zydus Lifesciences Ltd.
